Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 3
2010 1
2012 1
2013 1
2014 1
2015 3
2016 11
2017 27
2018 27
2019 36
2020 42
2021 30
2022 27
2023 33
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Results by year

Filters applied: . Clear all
Page 1
Atopic Dermatitis: Diagnosis and Treatment.
Frazier W, Bhardwaj N. Frazier W, et al. Am Fam Physician. 2020 May 15;101(10):590-598. Am Fam Physician. 2020. PMID: 32412211 Free article. Review.
Newer medications approved by the U.S Food and Drug Administration, such as crisaborole and dupilumab, are effective in treating atopic dermatitis but are currently cost prohibitive for most patients....
Newer medications approved by the U.S Food and Drug Administration, such as crisaborole and dupilumab, are effective in treating atop …
Atopic dermatitis.
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Weidinger S, et al. Nat Rev Dis Primers. 2018 Jun 21;4(1):1. doi: 10.1038/s41572-018-0001-z. Nat Rev Dis Primers. 2018. PMID: 29930242 Review.
Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection.
Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Fishbein AB, et al. J Allergy Clin Immunol Pract. 2020 Jan;8(1):91-101. doi: 10.1016/j.jaip.2019.06.044. Epub 2019 Aug 29. J Allergy Clin Immunol Pract. 2020. PMID: 31474543 Free PMC article. Review.
Now, multiple agents targeting specific disease pathways are available or in development. Two new therapies, crisaborole and dupilumab, have become available since 2016, and dupilumab has dramatically improved outcomes for adults with severe AD. This article provides an ov …
Now, multiple agents targeting specific disease pathways are available or in development. Two new therapies, crisaborole and dupiluma …
New treatments in atopic dermatitis.
Puar N, Chovatiya R, Paller AS. Puar N, et al. Ann Allergy Asthma Immunol. 2021 Jan;126(1):21-31. doi: 10.1016/j.anai.2020.08.016. Epub 2020 Aug 17. Ann Allergy Asthma Immunol. 2021. PMID: 32818591 Review.
Moreover, 2 newer targeted medications are now approved by the Food and Drug Administration for both children and adults, crisaborole 2% ointment and dupilumab, with several others in the therapeutic pipeline. ...
Moreover, 2 newer targeted medications are now approved by the Food and Drug Administration for both children and adults, crisaborole …
What's New in Topicals for Atopic Dermatitis?
Kleinman E, Laborada J, Metterle L, Eichenfield LF. Kleinman E, et al. Am J Clin Dermatol. 2022 Sep;23(5):595-603. doi: 10.1007/s40257-022-00712-0. Epub 2022 Sep 1. Am J Clin Dermatol. 2022. PMID: 36048410 Free PMC article. Review.
First-line therapy for acute management of AD includes topical therapies such as corticosteroids, calcineurin inhibitors, and, more recently, the phosphodiesterase inhibitor crisaborole. Topical agents have remained the mainstay therapy for decades; however, there has been …
First-line therapy for acute management of AD includes topical therapies such as corticosteroids, calcineurin inhibitors, and, more recently …
Clinical practice guidelines for the diagnosis and management of atopic dermatitis.
Kulthanan K, Tuchinda P, Nitiyarom R, Chunharas A, Chantaphakul H, Aunhachoke K, Chularojanamontri L, Rajatanavin N, Jirapongsananuruk O, Vichyanond P, Chatchatee P, Sangsupawanich P, Wananukul S, Singalavanija S, Trakanwittayarak S, Rerkpattanapipat T, Thongngarm T, Wisuthsarewong W, Limpongsanurak W, Kamchaisatian W, Noppakun N. Kulthanan K, et al. Asian Pac J Allergy Immunol. 2021 Sep;39(3):145-155. doi: 10.12932/AP-010221-1050. Asian Pac J Allergy Immunol. 2021. PMID: 34246205 Free article.
Other therapies, including antimicrobial agents, systemic antihistamines, systemic anti-inflammatory agents, immunotherapy, phototherapy, and psychotherapy, are reviewed in these guidelines. Crisaborole, a new topical phosphodiesterase 4 inhibitor, can be used twice daily …
Other therapies, including antimicrobial agents, systemic antihistamines, systemic anti-inflammatory agents, immunotherapy, phototherapy, an …
Diagnosis and Management of Dermatitis, Including Atopic, Contact, and Hand Eczemas.
Chan CX, Zug KA. Chan CX, et al. Med Clin North Am. 2021 Jul;105(4):611-626. doi: 10.1016/j.mcna.2021.04.003. Med Clin North Am. 2021. PMID: 34059241 Review.
Therapeutic options highlighted are moisturizers, topical corticosteroids, topical calcineurin inhibitors, crisaborole, phototherapy, and systemic medications including biologics....
Therapeutic options highlighted are moisturizers, topical corticosteroids, topical calcineurin inhibitors, crisaborole, phototherapy, …
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
Li H, Zuo J, Tang W. Li H, et al. Front Pharmacol. 2018 Oct 17;9:1048. doi: 10.3389/fphar.2018.01048. eCollection 2018. Front Pharmacol. 2018. PMID: 30386231 Free PMC article. Review.
Over the past decades, numerous PDE4 inhibitors have been designed and synthesized, among which roflumilast, apremilast, and crisaborole were approved for the treatment of inflammatory airway diseases, psoriatic arthritis, and atopic dermatitis, respectively. ...
Over the past decades, numerous PDE4 inhibitors have been designed and synthesized, among which roflumilast, apremilast, and crisaborole …
Treatment options for moderate to severe atopic dermatitis.
Wallace DV. Wallace DV. Allergy Asthma Proc. 2022 Nov 1;43(6):474-493. doi: 10.2500/aap.2022.43.220076. Allergy Asthma Proc. 2022. PMID: 36335413 Review.
Second-line topical agents include calcineurin inhibitors, e.g., tacrolimus and pimecrolimus; crisaborole; and ruxolitinib. For acute flares, cyclosporine is preferred over systemic corticosteroids. ...
Second-line topical agents include calcineurin inhibitors, e.g., tacrolimus and pimecrolimus; crisaborole; and ruxolitinib. For acute …
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. Crocetti L, et al. Molecules. 2022 Aug 4;27(15):4964. doi: 10.3390/molecules27154964. Molecules. 2022. PMID: 35956914 Free PMC article. Review.
Since then, three additional compounds have reached the market a few years later: Crisaborole for atopic dermatitis, Apremilast for psoriatic arthritis and Ibudilast for Krabbe disease. ...
Since then, three additional compounds have reached the market a few years later: Crisaborole for atopic dermatitis, Apremilast for p …
224 results